Optimizing patient access with evidence of product value, effectiveness, and safety from early development through loss of exclusivity.

Learn More
thought leadership
Upcoming Conferences

Engage with our staff at upcoming scientific, clinical, and business meetings around the world

Learn More
Evidence Synthesis, Modeling & Communication

Favorable and timely coverage decisions require careful articulation of a product’s value story

Our Evidence Synthesis, Modeling & Communication team can help create a unified value story and body of evidence

Learn More
Featured Articles

Read Evidera’s featured articles in the latest issue of pharmaphorum Deep Dive

Discover our experts’ take on disruptive technologies in “Machine learning: Opening doors in pharmaceutical development“ and “Data disruption and applying ‘enabled intelligence’”

Read Now
A patient speaks with her doctor.
Patient Engagement

Evidera is committed to engaging with patients as partners and to that end, we are excited to have Erem Latif join our Patient-Centered Research team as director of patient engagement

Read Her Bio
Latest News

Collaboration with China-based HLT creates opportunity to expand access to real-world data and patients in China

Learn More

Our Work In Action

150+ Drugs/Therapies

supported in the past year

30+ Global Extended Access Programs

in the last 3 years alone with thousands of patients transitioning smoothly from investigational to commercial

130+ Payer Submissions

across 20+ countries in the past 5 years, including reversal of multiple NICE decisions

17 of the 20 Top-Selling Drugs

in 2017 supported in the past 5 years

130+ Peer-Reviewed Publications

and 220+ research posters and presentations per year

Learn More

Latest Publications

Oncology

Comprehensive Validation of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) Anorexia/Cachexia Subscale (A/CS) in Lung Cancer Patients with Involuntary Weight Loss

  • Quality of Life Research
  • March 2019
Cardiovascular

Comparison of Recommendations and Use of Cardiovascular Risk Equations by Health Technology Assessment Agencies and Clinical Guidelines

  • Value Health
  • March 2019
Oncology

Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada

  • PharmacoEconomics - Open
  • March 2019
Read More About Our Publications
What We Do

What We Do

Real-World Evidence

Obtain real-world evidence of value by extracting data from existing sources, collecting primary data, and conducting hybrid studies.

Patient-Centered Research

Develop and evaluate clinical outcomes assessments to support labeling and promotional claims.

Evidence Synthesis, Modeling & Communication

Provide a truly connected value story, supported by strong evidence

Market Access

Optimize market access with cogent payer insights, expert-informed evidence strategy, and persuasive communication of product value.

Interventional Studies

Provide peri- and post-approval evidence via dedicated global operations and custom-tailored study designs.

Pragmatic Studies

Explore patient-centered outcomes and comparative effectiveness using pragmatic studies with adaptive designs.

Medical Writing

Expert medical writing, including medical information, study documentation, and publications, tailored to the peri- and post-approval environment.
ReitsmaDir

In Our Own Words

We are optimizing protocol development and operations in oncology trials, including better anticipation of post-approval needs that can be integrated earlier into trial designs, providing crucial data for activities focused on market access.

CUP Case Study
Case Study

Robust Modeling Helped Convince NICE to Reverse Their Decision

Learn how Evidera’s experts helped to improve access to a mCRPC treatment in a country with traditionally conservative reimbursement for these therapies.

Read More
Case Study

Compassionate Use Program: Rapid Drug Delivery to Patients in Need

Learn how Evidera, as part of PPD, created a global program across 38 countries to provide treatment within 24-48 hours to 3,100 patients.

Read More
Careers

Meaningful Work at Every Level

We assess candidates across a variety of scientific and operational functions. From leaders in their fields, to those who are new to the industry. We employ people who have a proactive mind-set when it comes to the work they do and helping the people they work with.

Learn More